Acknowledging that until 20 some years ago the treatment of MS patients focused mainly on treating relapses with systemic corticosteroids and providing various symptomatic treatment, the introduction of interferon beta therapies in 1993 (interferon beta‐1b) and in 1996 (interferon beta‐1a) fundamentally changed the MS treatment paradigm. Here, IFNB1 is linked to myeloid sarcoma.